The Rhythm (ASX:RHY) share price surges on cancer testing milestone

The Rhythm Biosciences Ltd (ASX: RHY) share price has surged 6% higher on Tuesday as the company takes a step closer to commercialisation

| More on:
ASX bank profit upgrade Red rocket and arrow boosting up a share price chart

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Rhythm Biosciences Ltd (ASX: RHY) share price has opened higher on Tuesday after the successful completion of Study 6 for its ColoSTAT product. At the time of writing, the Rhythm share price is trading at $1.60, up 6.33%.

Let's take a closer look at this announcement and what it means for the Rhythm share price.

Why the Rhythm share price opened higher on Tuesday 

The Rhythm share price has surged. Climbing from a low of 3.5 cents 12-months ago to a high of $1.675 on 2 March. The company continues to hit significant milestones. In particular, for the commercialisation of its simple, affordable, and effective ColoSTAT blood test. This test focuses specifically on the early detection of colorectal cancer, the third-largest cause of cancer-related deaths globally. 

Today, the company announced the successful completion of Study 6 for ColoSTAT. Study 6 confirmed that the third-party commercially manufactured ColoSTAT prototype test-kid demonstrated a high level of accuracy for the detection of colorectal cancer via a simple blood test. 

This test utilised a third-party, commercially developed test-kit which proved that the test was reproducible, salable and consistent. Study 6 demonstrated an increase in performance over Rhythm's earlier testing results announced in November 2020.

The company will now progress to Study 7, which involves a ~1000 patient clinical trial across ten clinical trial sites. The newly appointed sites will provide geographical diversity across four states. These trials will ultimately support regulatory submissions. In particular, for the Conformitè Europëenne (CE) Mark and the Therapeutic Goods Administration (TGA) in Australia. 

Rhythm share price eyes global opportunity 

Rhythm highlights the growing burden of colorectal cancer in the US. The US Preventative Services Task Force currently recommends the screening age to be reduced from 50 to 45 years. This would increase the targeting screening population in the US to ~144 million people, up from 94 million. The US Centres for Medicare and Medicaid Services has also released a draft decision outlining the criteria for reimbursement of current and future blood-based colorectal cancer screening tests. Rhythm also notes that its ColoSTAT testing kid would be able to meet the requirements for reimbursement eligibility in the US. This comment was based on the Study 6 performance. 

Comments from the CEO

Rhythm CEO, Glenn Gilbert is pleased with the company's results today and eyes future opportunities to commercialise the ColoSTAT test:

We continue to target ColoSTAT® as a disruptive cancer detection technology for the global mass screening market to address the growing burden of colorectal cancer. The completion, increase in performance and generally positive outcome of Study 6, is a critical milestone for the Company as we progress our clinical trial, and importantly, how we now consider our entry plans for the global markets, including the US.

Additionally, in Rhythm's half-year results, the company notes that it remains fully funded to execute its development plan. Furthermore, Rhythm ended the December 2020 period with a cash balance of $6.02 million. 

Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

asx share price represented by cartoon letters spelling the word FOMO
Share Market News

What did Macquarie's "FOMO Meter" reveal about the stock market in May?

Is the market getting frothy or is there still room to climb?

Read more »

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Dateline, DroneShield, Ora Banda, and Pilbara Minerals shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Share Gainers

Why BHP, Coronado Global, EBR Systems, and Whitehaven Coal shares are pushing higher today

These shares are ending the week on a positive note. Let's find out why.

Read more »

man thinking about whether to invest in bitcoin
Broker Notes

Why Macquarie expects this ASX 200 dividend stock to keep outperforming

Macquarie has tipped this ASX 200 dividend stock to outperform. Let’s find out why.

Read more »